central nervous system localized malignant lymphoma.
Conditions
Interventions
Product Name: 89Zirkonium-rituximab
Pharmaceutical Form: Solution for injection
Sponsors
UMC Utrecht
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - Patients who have signed informed consent - Age = 18 years - MR suspicion of a primary CNS lymphoma (homogeneous contrast enhancement, low MRI ADC values). - Planned diagnostic biopsy Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 8 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 2
Exclusion criteria
Exclusion criteria: - Pregnancy - Contra-indications for brain biopsy e.g. coagulation disorder or poor clinical condition assessed as unfit for surgical procedure.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: The objective of the study is to confirm that PCNSL is positive on 89Zr-rituximab PET imaging.;Secondary Objective: Not applicable;Primary end point(s): The main outcome of the study is the performance of 89Zr- rituximab PET/CT in diagnosing CSN lymphoma. ;Timepoint(s) of evaluation of this end point: 2 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): not applicable;Timepoint(s) of evaluation of this end point: not applicable | — |
Countries
Netherlands
Contacts
Public ContactClinical Research Coordinator
UMC Utrecht
Outcome results
None listed